# US 2021/0275720 A1 · Methods and compositions for the treatment of degenerate bone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275720 A1
- Document ID: US20210275720A1
- Status: Published application
- Kind: A1
- Application number: 17/070,183
- Filed: 2020-10-14
- Published: 2021-09-09
- Earliest claimed: 2016-04-27
- Assignees: Anika Therapeutics, Inc.
- Applicants: Anika Therapeutics, Inc.
- Inventors: Edward S. Ahn; Chia-En Lin; Colin D. White
- Web page: https://patentgrep.com/patent/US20210275720A1

## CPC

- A61L 27/20: Polysaccharides
- A61B 17/3472: {for bones, e.g. intraosseus injections}
- A61B 17/8816: {characterised by the conduit, e.g. tube, along which fluid flows into the body or by conduit connections}
- A61B 17/8825: {characterised by syringe details (A61B17/8822, A61B17/8827 take precedence)}
- A61B 17/8833: {Osteosynthesis tools specially adapted for handling bone cement or fluid fillers; Means for supplying bone cement or fluid fillers to introducing tools, e.g. cartridge handling means}
- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61L 24/0036: {Porous materials, e.g. foams or sponges}
- A61L 24/0042: {Materials resorbable by the body}
- A61L 24/0084: {containing fillers of phosphorus-containing inorganic compounds, e.g. apatite}
- A61L 27/025: {Other specific inorganic materials not covered by A61L27/04 - A61L27/12}
- A61L 27/12: Phosphorus-containing materials, e.g. apatite
- A61L 27/46: with phosphorus-containing inorganic fillers
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61B 2017/00893: {pharmaceutically effective}
- A61B 2017/8838: {for mixing bone cement or fluid fillers}
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (“OA”), rheumatoid arthritis, and avascular necrosis.

## Claims

### Claim 1

An injectable biomaterial comprising:
(a) a solid component; and
(b) a liquid component comprising a carbohydrate;
wherein the injectable biomaterial sets and cures to form an apatitic crystal structure after mixing of the solid component and the liquid component;
wherein the ratio of solid component to liquid component is about 3 to about 1 by mass; and
wherein the fully set and cured injectable biomaterial comprises a median pore diameter of less than about 1 μm.

### Claim 2 (depends on 1)

A method for making the injectable biomaterial of claim 1, the method comprising:
(a) creating the liquid component by:
(i) providing a liquid solution;
(ii) adjusting the pH of the liquid solution with a pH adjusting agent; and
(iii) dissolving the carbohydrate in the liquid solution to form a the liquid component;
(b) providing the solid component; and
(c) mixing the liquid component and the solid component to form the injectable biomaterial.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The injectable biomaterial of claim 1, wherein the solid component comprises at least one of a metal phosphate and a metal carbonate.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The injectable biomaterial of claim 1, wherein the solid component comprises at least one of α-tricalcium phosphate (Ca3(PO4)2), calcium carbonate (CaCO3), and calcium phosphate.

### Claim at position 7

9-20. (canceled)

### Claim 21 (depends on 1)

The injectable biomaterial of claim 1, wherein the carbohydrate is hyaluronic acid, or an ester, acylurea, acyl isourea, disulfide, or amide thereof.

### Claim 22 (depends on 21)

The injectable biomaterial of claim 21, wherein the hyaluronic acid is selected from the group consisting of hyaluronan, sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, ammonium hyaluronate, and combinations thereof.

### Claim at position 10

23-26. (canceled)

### Claim 27 (depends on 21)

The injectable biomaterial of claim 21, wherein the hyaluronic acid comprises a hyaluronic ester.

### Claim at position 12

28-56. (canceled)

### Claim 57 (depends on 1)

The injectable biomaterial of claim 1, wherein the ratio of solid component to liquid component is about 1.5 to about 1 by mass.

### Claim 58 (depends on 57)

The injectable biomaterial of claim 57, wherein the ratio of solid component to liquid component is about 1 to about 1 by mass.

### Claim at position 15

59-110. (canceled)

### Claim 111 (depends on 1)

The injectable biomaterial of claim 1, wherein the curing of the injectable biomaterial yields an apatitic crystal structure that is at least about 90% hydroxyapatite.

### Claim at position 17

112-117. (canceled)

### Claim 118 (depends on 1)

The injectable biomaterial of claim 1, wherein the fully set and cured injectable biomaterial has a molar Ca/P ratio of about 1 to about 2.

### Claim at position 19

119-178. (canceled)

### Claim 179 (depends on 1)

A method of treating an affected area of a bone in a patient in need thereof, the method comprising:
a) identifying the affected area in the bone of the patient;
b) creating in the bone an incision through a cortical wall of the bone to provide access to a degenerate cancellous space in the affected area of the bone;
c) administering a volume of an injectable biomaterial of claim 1 through the incision through the cortical wall of the bone and into the degenerate cancellous space.

### Claim 180 (depends on 179)

The method of claim 179, wherein the affected area of bone is adjacent to a joint of the patient in which the patient is experiencing a joint pathology.

### Claim 181

(canceled)

### Claim 182 (depends on 179)

The method of claim 179, wherein the joint pathology is selected from the group consisting of pain, osteoarthritis, rheumatoid arthritis, avascular necrosis, and combinations thereof.

### Claim 183 (depends on 179)

The method of claim 179, wherein the method is for the treatment of osteoarthritis in a joint of the patient.

### Claim at position 25

184-209. (canceled)

### Claim 210 (depends on 179)

The method of claim 179, wherein providing the access to the cancellous space comprises creating a channel in the bone of the patient to couple the incision in the cortical wall of the bone to the cancellous space comprising the affected area.

### Claim at position 27

211-222. (canceled)

### Claim 223 (depends on 179)

The method of claim 179, further comprising decompressing and aspirating the contents of the affected area prior to administration of the injectable biomaterial to the affected area.

### Claim at position 29

224-225. (canceled)

### Claim 226 (depends on 223)

The method of claim 223, wherein the contents comprise a fluid.

### Claim 227 (depends on 226)

The method of claim 226, wherein the fluid comprises at least one of inflammatory mediators and non-inflammatory mediators.

### Claim at position 32

228-248. (canceled)

### Claim 249 (depends on 179)

The method of claim 179, wherein the injectable biomaterial is injected into the affected area while minimally disrupting the subchondral plate.

### Claim at position 34

250-255. (canceled)

### Claim 256 (depends on 179)

The method of claim 179, wherein the injectable biomaterial flows into the porosity of cancellous bone during administration into the affected area.

### Claim 257 (depends on 179)

The method of claim 179, wherein the injectable biomaterial remains cohesive and substantially fills bone voids during administration into the affected area.

### Claim 258

(canceled)

### Claim 259 (depends on 179)

The method of claim 179, wherein the injectable biomaterial prevents diffusional passage of at least one of inflammatory mediators and non-inflammatory mediators from the adjacent joint space into the affected area.

### Claim at position 39

260-267. (canceled)

### Claim 268 (depends on 1)

A kit comprising:
(a) the solid component and the liquid component for preparing the injectable biomaterial of claim 1; and
(b) instructions for use of the same.

### Claim at position 41

269-279. (canceled)

### Claim 280 (depends on 268)

The kit of claim 268, wherein the solid component is disposed in a syringe possessing an integrated mixing device for in situ mixing of premeasured portions of the solid component and the liquid component to form the injectable biomaterial.

### Claim at position 43

281-283. (canceled)
